As a result, all these antibodies partially reduced the therapeutic potency of NvIH, suggesting that NK cells, CD4+ cells, and CD8α+ cells are all critical to NvIH-mediated tumor therapy (fig. The gene discussed is CD8A; the disease is neoplasm.